Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
RESEARCH LETTER
No genetic causal links detected between antihypertensive medications and bladder cancer: insights from a trans-ancestry, drug-target Mendelian randomization analysis
1
Nantong Health College of Jiangsu Province, China
2
Nantong First People's Hospital, China
3
Rafsanjan University of Medical Sciences, Iran
4
Affiliated Nantong Hospital of Nanjing University of Chinese Medicine, China
5
Clinical Research Unit, Affiliated Hospital of Nantong University, Nantong, China
These authors had equal contribution to this work
Submission date: 2024-11-23
Final revision date: 2025-02-28
Acceptance date: 2025-03-28
Online publication date: 2025-04-22
Corresponding author
Hai-Yan Hao
Clinical Research Unit, Affiliated Hospital of Nantong University, Nantong, China., China
Clinical Research Unit, Affiliated Hospital of Nantong University, Nantong, China., China
TOPICS
REFERENCES (32)
1.
Dobruch J, Oszczudłowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas) 2021; 57: 749.
2.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; 71: 96-108.
3.
Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am 2021; 35: 531-41.
4.
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223-49.
5.
Sanghvi MM, Dhall E, Chahal CAA, et al. Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes 2025; qcae117.
6.
Bettiol A, Lucenteforte E, Vannacci A, et al. Calcium channel blockers in secondary cardiovascular prevention and risk of acute events: real-world evidence from nested case-control studies on Italian hypertensive elderly. Clin Drug Investig 2017; 37: 1165-74.
7.
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017; 1: CD002003.
8.
Chuang YW, Yu MC, Huang ST, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study. J Hypertens 2017; 35: 170-7.
9.
Jiang X, Castelao JE, Yuan JM, et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis 2010; 31: 1964-71.
10.
Xiong J, Yang L, Deng YQ, et al. The causal association between smoking, alcohol consumption and risk of bladder cancer: a univariable and multivariable Mendelian randomization study. Int J Cancer 2022; 151: 2136-43.
11.
Adolphe C, Xue A, Fard AT, Genovesi LA, Yang J, Wainwright BJ. Genetic and functional interaction network analysis reveals global enrichment of regulatory T cell genes influencing basal cell carcinoma susceptibility. Genome Med 2021; 13: 19.
12.
Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J 2023; 44: 4913-24.
13.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-89.
14.
Smith GD, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23: R89-98.
15.
Shoji-Asahina A, Usui T, Tabara Y. U-shaped association between blood pressure and all-cause mortality in older adults: the Shizuoka study. J Hum Hypertens 2025; 39: 66-71.
16.
Kishore SP, Blank E, Heller DJ, et al. Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases. J Am Coll Cardiol 2018; 71: 564-74.
17.
Wang S, Xie L, Zhuang J, et al. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer 2023; 23: 425.
18.
Copland E, Canoy D, Nazarzadeh M, et al. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol 2021; 22: 558-70.
19.
Yang R, Zhang Y, Liao X, Yao Y, Huang C, Liu L. The relationship between anti-hypertensive drugs and cancer: anxiety to be resolved in urgent. Front Pharmacol 2020; 11: 610157.
20.
Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009; 20: 477-82.
21.
Forde A, Hemani G, Ferguson J. Review and further developments in statistical corrections for Winner’s Curse in genetic association studies. PLoS Genet 2023; 19: e1010546.
22.
Zhao X, Wang Y, Liang C. Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis. Int Urol Nephrol 2022; 54: 1169-85.
23.
Zheng G, Chattopadhyay S, Sundquist J, Sundquist K, Ji J. Antihypertensive drug targets and breast cancer risk: a two-sample Mendelian randomization study. Eur J Epidemiol 2024; 39: 535-48.
24.
Du K, Li A, Zhang CY, Li SM, Chen P. Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study. Front Pharmacol 2024; 15: 1448319.
25.
Xie Y, Xu P, Wang M, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging (Albany NY) 2020; 12: 1545-62.
26.
Fan B, Schooling CM, Zhao JV. Genetic proxies for calcium channel blockers and cancer: a Mendelian randomization study. J Hum Hypertens 2023; 37: 1028-32.
27.
Chen CY. Mendelian randomization: methods for causal inference using genetic variants 2nd edition. Biometrics 2023; 79: 2771-2.
28.
Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Meth Med Res 2007; 16: 309-30.
29.
Goławski M, Lejawa M, Banach M, Jóźwiak J, Gierlotka M, Osadnik T. Association between Lp(a) and T2D: a Mendelian randomization study. Arch Med Sci 2024; 20: 1002-5.
30.
Zhou J, Li Y, Lin Y, et al. The genetic causal association between hip or knee osteoarthritis and frailty: a two-sample Mendelian randomization analysis. Arch Med Sci 2024; 20: 938-46.
31.
Zeng X, Juaiti M, Tang Y, Wang R, Liu D. Circulating micronutrients and risk of stroke: a Mendelian randomisation and cross-sectional observational study. Arch Med Sci 2024; 20: 2034-8.
32.
Xu X, Wang SY, Wang R, et al. Association of antihypertensive drugs with psoriasis: a trans-ancestry and drug-target Mendelian randomization study. Vascul Pharmacol 2024; 154: 107284.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
